Motivation for the study: Treatment options for HER2-positive breast cancer were evaluated, focusing on the efficacy and safety of trastuzumab-emtansine (T-DM1) compared to other anti-HER2 therapies. The gene discussed is ERBB2; the disease is breast carcinoma.